In recent years, our group developed multifunctional nanoliposomes, composed of sphingomyelin (Sm) and cholesterol (Chol) and bifunctionalized with phosphatidic acid (PA) and with a peptide (mApoE) derived from the receptor-binding domain of apolipoprotein E (named mApoE-PA-LIPs) as a candidate for the treatment of AD.2–4 The presence of PA has been shown to confer to LIPs strong affinity for Aβ in different aggregation forms; mApoE-derived molecules, instead, improve the passage of nanoliposomes across the BBB either in vitro or in vivo.5 Here, APOE is linked to Alzheimer disease.